Ara-290 dosage chart

Reconstitution steps

1. 1Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall; avoid foaming.
3. 3Gently swirl or roll until fully dissolved (do not shake vigorously).
4. 4Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and injection site to maintain consistency.
• No clinically significant adverse effects were reported at 4 mg/day in 28-day clinical trials.

How This Works

Ara-290 (cibinetide) binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131 (βc subunit), which is distinct from the classical erythropoietin receptor. This selective binding triggers anti-apoptotic and anti-inflammatory signaling cascades that protect tissues and promote repair without stimulating erythropoiesis. Preclinical research demonstrates that Ara-290 can reprogram a pro-inflammatory, tissue-damaging environment into one favoring healing and regeneration. Additionally, analgesic effects have been observed through immunomodulation and direct inhibition of TRPV1 ion channels activated by capsaicin.

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

• Neuroprotection: Clinical trials in diabetic neuropathy showed improvements in HbA1c, lipid profiles, and neuropathic pain scores with 4 mg daily dosing.
• Nerve regeneration: In sarcoidosis-associated small-fiber neuropathy, treatment led to significant increases in corneal nerve fiber density (objective nerve regrowth) and improved symptoms compared to placebo.
• Tissue protection: Anti-inflammatory and anti-apoptotic effects observed across multiple organ systems in preclinical models.
• No erythropoietic effects: Unlike full EPO, Ara-290 does not stimulate red blood cell production, avoiding related side effects.
• Tolerability: Well tolerated in clinical studies; occasional mild injection-site reactions (redness, transient discomfort) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies that may support therapeutic goals.

• Optimize glycemic control through diet and medication adherence if addressing diabetic neuropathy.
• Incorporate regular physical activity appropriate to individual capacity to support nerve health and circulation.
• Prioritize adequate sleep and stress management to support tissue repair processes.
• Avoid smoking and limit alcohol consumption, both of which can exacerbate neuropathic conditions.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

• Clean the vial stopper and injection site with alcohol swabs; allow to dry completely.
• Select a fatty subcutaneous site: lower abdomen (at least 2 inches from navel), outer thigh, or back of upper arm.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
• Aspiration is not required for subcutaneous injections; inject slowly and steadily.
• Rotate sites systematically with each dose to avoid lipohypertrophy and local tissue changes.
• After injection, withdraw the needle and apply gentle pressure with clean gauze; do not rub the site.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Ara-290 dosage FAQs